|
Variable
|
Number of patientsa
|
% total
|
Number with metastasis
|
% metastasis
|
|---|
|
Sex
|
|
Female
|
139
|
36.7%
|
29
|
20.9%
|
|
Male
|
240
|
63.3%
|
52
|
21.7%
|
|
Age
|
|
≤60
|
157
|
41.4%
|
41
|
26.1%
|
|
60–70
|
154
|
40.6%
|
29
|
18.8%
|
|
> 70
|
68
|
17.9%
|
11
|
16.2%
|
|
Familial risk
|
|
Low
|
196
|
51.7%
|
34
|
17.3%
|
|
Intermediate/High
|
183
|
48.3%
|
47
|
25.7%
|
|
5-FU based treatment
|
|
5-FU treated
|
214
|
56.5%
|
59
|
27.6%
|
|
Other/No chemo
|
159
|
42.0%
|
17
|
10.7%
|
|
Unknown
|
6
|
1.6%
|
5
|
83.3%
|
|
Stage
|
|
I
|
81
|
21.4%
|
8
|
9.9%
|
|
II
|
158
|
41.7%
|
30
|
19.0%
|
|
III
|
140
|
36.9%
|
43
|
30.7%
|
|
Location
|
|
Colon
|
233
|
61.5%
|
41
|
17.6%
|
|
Rectum
|
146
|
38.5%
|
40
|
27.4%
|
|
Histology
|
|
Non-mucinous
|
343
|
90.5%
|
75
|
21.9%
|
|
Mucinous
|
36
|
9.5%
|
6
|
16.7%
|
|
Vascular invasion
|
|
Absence
|
242
|
63.9%
|
45
|
18.6%
|
|
Presence
|
111
|
29.3%
|
30
|
27.0%
|
|
Unknown
|
26
|
6.9%
|
6
|
23.1%
|
|
Lymphatic invasion
|
|
Absence
|
237
|
62.5%
|
44
|
18.6%
|
|
Presence
|
116
|
30.6%
|
31
|
26.7%
|
|
Unknown
|
26
|
6.9%
|
6
|
23.1%
|
|
BRAF V600E mutation
|
|
Absence
|
333
|
87.9%
|
72
|
21.6%
|
|
Presence
|
19
|
5.0%
|
8
|
42.1%
|
|
Unknown
|
27
|
7.1%
|
1
|
3.7%
|
- a Patients with MSI-H tumors and Stage IV patients were excluded. 5-FU: 5-fluorouracil
